Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line

Abstract

The existence of several model systems with which to investigate a particular disease is advantageous for researchers. This is especially true for ovarian cancer, which, due to its complex and heterogeneous nature, inherently requires a large number of model systems. Here, we report a new ovarian serous adenocarcinoma cell line, designated YDOV-157, and characterized via post genomics and post proteomics. In this study, primary culture of tumor cells from ascites was performed and the cells were immortalized up to at least 60 passages in vitro. We studied the morphologies, cell proliferation, BRCA1/2 mutations, tumorigenesis capacity, and chemosensitivity of YDOV-157. Using a cDNA microarray, differentially expressed genes were identified and some of them were validated. Using proteomic analysis, we identified proteins that were differentially expressed in YDOV-157. The newly derived cell line, designated YDOV-157, grew as a monolayer and the doubling time was 102 h. When transplanted into nude mice, it initiated the formation of tumor masses with microscopic findings identical to those of the primary tumor. Chemosensitivity test showed that paclitaxel induced the highest chemosensitivity index. In microarray analysis, 2,520 probes were differently expressed, compared to human ovarian surface epithelial cells (HOSEs). In SYBR Green real-time PCR, the expression of E2F2 (P = 0.040) and CRABP2 genes (P = 0.030) was significantly higher in the ovarian cancer cell lines than in HOSEs. Furthermore, proteomic analysis showed that expression of 28 spots was significantly altered between YDOV-157 and HOSE. In conclusion, the newly derived YDOV-157 cell line may be an important research resource for studying cancer cell biology and should also be very useful for developing new strategies that inhibit cancer cell growth and progression.

The role of S100A14 in epithelial ovarian tumors

“…Five EOC cell lines (YDOV-13, YDOV-151, YDOV-139, YDOV-161, and YDOV-13) and 6 human ovarian surface epithelial (HOSE) cells, which were established and characterized in our laboratory, were cultured as described previously [28,29]. SNU-840 was purchased from Korean Cell Line Bank (KCLB, Seoul, Korea).…”

Expression of stress‐induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer

“…The general characteristics of these cell lines are described in Supporting Information Table . Detailed culture procedures are described elsewhere (Cho et al, ). Briefly, TOV112D, OVCAR3, and OVCA429 were maintained in DMEM/F12 supplemented with 10% fetal bovine serum (FBS) (Gemini Bio‐Products, Calabasas, CA) and YDOV‐13, −105, −139, and −151 were grown in a mixture of Medium 199 and MCDB 105 (1:1) (Sigma, St Louis, MO) supplemented with 10% FBS (Gemini Bio‐Products).…”

ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139

“…The procedures of polymerase chain reaction (PCR) for mycoplasma contamination of the cell lines were the same as previously described (8,9).…”

“…The procedures of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for chemosensitivity test were as previously described (9).…”

“…Gene expression profiling was performed as previously reported using cDNA microarrays (9). Briefly, total RNA was extracted from YDOV-139 and 3 HOSE cells (HOSE 198,209, and 211) using TRIzol (Invitrogen, Carlsbad, CA) and purified using RNeasy columns (Qiagen).…”